Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and…
Leap Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for DKN-01 for the treatment of gastric and…
Read More...
Read More...